ESMO 2019: Results from the TRAXAR study to assess TRC105 plus axitinib for metastatic kidney cancer

Results from the TRAXAR clinical trial to assess TRC105 plus axitinib in pre-treated patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Endoglin is an endothelial cell surface receptor that has a role in the development and growth of blood vessels (angiogenesis) […]

read more

Tracon Pharmaceuticals present results from phase 1b trial of TCR105 plus axitinib in kidney cancer

TRACON Pharmaceuticals presented final results from a phase 1b clinical trial combining TRC105 with Inlyta® (axitinib) in patients with advanced or metastatic renal cell carcinoma (RCC) at the European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark, earlier this week. This study was an open-label, dose escalation and expansion phase 1b study, which enrolled a total […]

read more
Showing all 2 results